Sunitinib is a Medicine belongs to Antineoplastic group whose information about Brand can be referenced from   Book : Martindale    Page : 851   Edition : 37  

  ►   Brandname : Sutent
  ►  Strength : Capsule with 12.5 mg.  Capsule with 25 mg.  Capsule with 50 mg. 

Reference of this Medicine for its Strength can be taken from   Book : Martindale    Page : 851   Edition : 37  
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral
Reference :-   Book : Martindale    Page : 851   Edition : 37  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Gastrointestinal stromal tumours and advanced and/or metastatic renal cell carcinoma Oral 50 mg Capsule The recommended dose is 50 mg once daily, for 4 weeks of a 6-week treatment cycle. Doses may be increased or decreased in steps of 12.5 mg, based on individual tolerability. UK licensed product information recommends that the daily dose should not normally exceed 75 mg nor be decreased below 25 mg.

Ref :-  Book : Martindale    Page : 852   Edition : 37  

Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  

Ref :- Book :    Page :    Edition :   
►  Side Effect : Gastrointestinal disturbances, Anorexia, Headache, Fatigue, Fever, Hypertension, Hypothyroidism, Mouth pain or irritation, Dry mouth, Mucosal inflammation, Oedema, taste disturbances, Arthralgia, Myalgia, Myelosuppression, Dizziness, Paresthesia, Dyspnoea, Alopecia, Yellow skin discoloration, Chromaturia, Depigmentation of the hair or skin, Dryness, Rashes, Exfoliative dermatitis, Palmar-plantar syndrome, Gastrointestinal perforation, , There is an increased risk of bleeding at all sites; epistaxis is the most common treatment-related bleeding event but fatal pulmonary haemorrhage has occurred in patients with lung cancer. Pulmonary embolism or venous thromboembolic events may occur., Increases in serum amylase and lipase concentrations have been seen and there are rare reports of pancreatitis and hepatic failure. There are also rare reports of seizures and reversible posterior leukoencephalopathy syndrome.
Ref :-   Book : Martindale    Page : 851   Edition : 37.  

►  Drug Interaction : Drug interaction of Sunitinib is with Azole Antifungal, Macrolide antibacterials, ,  Ketoconazole , Rifampicin , Dexamethasone , Phenytoin , Carbamazapine , Phenobarbital
Ref :-   Book : Martindale    Page : 852   Edition : 37.  

  ►    Mechanism of Drug Drug Interaction :  Sunitinib is metabolised primarily by the cytochrome P450 isoenzyme CYP3A4 to produce an active metabolite, which is further metabolised by CYP3A4. Ketoconazole increased exposure to sunitinib, and use with other potent inhibitors of CYP3A4 (such as other azole antifungals, macrolide antibacterials, HIV-protease inhibitors, or grapefruit juice) may also increase sunitinib concentrations. Conversely, use with rifampicin decreased exposure to sunitinib, and inducers of CYP3A4 (such as dexamethasone, phenytoin, carbamazepine, phenobarbital, or St John’s wort) may decrease plasma sunitinib concentrations.
Ref :-   Book : Martindale    Page : 852   Edition : 37.  

►  Contraindication : , Decreases in left ventricular ejection fraction (LVEF) have occurred with sunitinib; baseline and periodic evaluations of LVEF should be taken. Patients should be monitored for signs of congestive cardiac failure and therapy interrupted or stopped if they occur., Sunitinib may prolong the QT interval and should be used with caution in patients with a history of this, who are taking antiarrhythmics, or who have pre-existing cardiac disease, bradycardia, or electrolyte disturbances.
Ref :-   Book :    Page :    Edition : .   Martindale    Page : 851   Edition : 37.  
  ►  Mechanism of Action :   Sunitinib malate is an inhibitor of several receptor tyrosine kinases.
Ref :-   Book : Martindale    Page : 852   Edition : 37.  

Pathway of DIETARY Product

​   ► Act.Comp / Nutrient / Food / Herb as follows :- NA

DIETARY Substance Interactions

​   ► This Medicine interact with :- NA

ContraIndication DIETARY Substance

​   ► This Medicine contraindicate with :- NA

►   Route of Elimination :   Renal, Faecal
Ref :-   Book : Martindale    Page : 852   Edition : 37.  

►    Plasma Half-life :   Min value :-   40 hours,    Max value :-   60 hours.  
Ref :-   Book : Martindale    Page : 852   Edition : 37.  

►    Peak Plasma Concentration :   Min value :-   6 hours,    Max value :-   12 hours.  
Ref :-   Book : Martindale    Page : 852   Edition : 37.